The Effect of Beta-glucan in Non-Small Cell Lung Cancer
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Checked against the public recordLast updated Jan 10, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Basic Science
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Louisville
- Interventions being studied
- Dietary Supplement: beta-glucan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
AIM 2: Inclusion Criteria: * suspected or definitive diagnosis of non-small cell lung cancer (NSCLC) * treatment naive or no treatment within 6 months prior to enrollment * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements AIM 3: Inclusion Criteria: * resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon * treatment naive * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * must be an operative candidate * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- James Graham Brown Cancer CenterLouisville, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 10, 2025. Always confirm current availability with the study team.